The importance of HLA DRB1 gene allele to clinical features and disability in patients with multiple sclerosis in Lithuania
详细信息 查看全文
- 作者：Renata Balnyte (1)
Daiva Rastenyte (1)
Antanas Vaitkus (1)
Dalia Mickeviciene (1)
Erika Skrodeniene (2)
Astra Vitkauskiene (2)
Ingrida Uloziene (3) - 刊名：BMC Neurology
- 出版年：2013
- 出版时间：December 2013
- 年：2013
- 卷：13
- 期：1
- 全文大小：164KB
- 参考文献：1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG: Multiple sclerosis. / N Engl J Med 2000, 343:938-52. CrossRef
2. Ramagopalan VS, Dobson R, Meier CU, Giovannoni G: Multiple sclerosis: risk factors, prodromes, and potential causal pathways. / Lancet Neurol 2010, 9:727-39. CrossRef
3. Ramagopalan VS, Ebers GC: Multiple sclerosis: major histocompatibility complexity and antigen presentation. / Genome Med 2009, 1:105-08. CrossRef
4. Oksenberg RJ, Baranzini ES: Multiple sclerosis genetics- is the glass half full, or half empty? / Nat Rev Neurol 2010, 6:429-37. CrossRef
5. Romeiro-Pinel L, Pujal JM, Martinez-Yelamos S, Gubierias L, Matas E, Bau L: HLA-DRB1: genetic susceptibility and disability progression in a Spanish multiple sclerosis population. / Eur J Neurol 2011, 18:337-42. CrossRef
6. Smestad C, Brynedal B, Jonasdottir G, Lorentzen AR, Masterman T, Akesson E, / et al.: The impact of the HLA-A and –DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients. / Eur J Neurol 2007, 14:835-40. CrossRef
7. Weatherby SJM, Thomson W, Pepper L, Donn R, Worthington J, Mann CLA, / et al.: HLA DRB1 and disease outcome in multiple sclerosis. / J Neurol 2001, 248:304-10. CrossRef
8. Hensiek AE, Sawcer SJ, Feakes R, Deans J, Mander A, Akesson E, / et al.: HLA-DR15 is associated with female sex and younger age at diagnosis in multiple sclerosis. / J Neurol Neurosurg Psychiatry 2002, 72:184-87. CrossRef
9. Kouri I, Papakonstantinou S, Bempes V, Vasiliadis HS, Kyritsis AP, Pelidou HS: HLA associations with multiple sclerosis in Greece. / J Neurol Sci 2011, 1-:28-1. CrossRef
10. Okuda DT, Srinivasan R, Oksenberg JR, Goodin DS, Baranzini SE, Beheshtian A, / et al.: Genotype-phenotype correlations in multiple sclerosis: HLA allele influence disease severity inferred by HMR spectroscopy and MRI measures. / Brain 2009, 132:250-59. CrossRef
11. Van der Walt A, Stankovich J, Bahlo M, Taylor BV, Van der Mei IAF, Foote SJ, / et al.: Heterogeneity at the HLA-DRB1 allelic variation locus does not influence multiple sclerosis disease severity, brain atrophy or cognition. / Mult Scler 2011, 17:344-52. CrossRef
12. World Health Organisation: / Multiple Sclerosis International Federation. Atlas Multiple Sclerosis resources in the world 2008. Geneva: World Health Organisation; 2008.
13. Balnyt? R, Rastenyt? D, Mickevi?ien? D, Vaitkus A, Skrodenien? E, Vitkauskien? A: Frequency of HLA-DRB1 Gene Alleles in Patients With Multiple Sclerosis in a Lithuanian Population. / Medicina (Kaunas) 2012, 1:9-4.
14. Polman CH, Reingold SC, Edan G: Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald criteria. / Ann Neurol 2005, 6:840-46. CrossRef
15. Celesia GG, Brigell MG: Recommended standards for pattern electroretinograms and visual evoked potentials. In / Recommendations for the practice of clinical neurophysiology: guidelines of the International Federation of Clinical Physiology (EEG,suppl 52:45-2). Edited by: Deuschl G, Eisen A. Elsevier science; 1999.
16. Siritho S, Freedman MS: The prognostic significance of cerebrospinal fluid in multiple sclerosis. / J Neurol Sci 2009, 279:21-5. CrossRef
17. Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, / et al.: Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis. / Arch Neurol 2005, 62:865-70. CrossRef
18. Olerup O, Zetterquist H: HLA-DRB typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. / Tissue Antigens 1992, 39:225-35. CrossRef
19. Silva AM, Pereira C, Bettencourt A, Carvalho C, Counto AR, Leite MI, / et al.: The role HLA-DRB* susceptibility and outcome of a Portuguese MS population. / J Neurol 2007, 1-:68-4.
20. Cree CAB, Reich ED, Khan O, De Jager PL, Nakashima I, Takahashi T, / et al.: Modification of multiple sclerosis phenotypes by African Ancestry at HLA. / Arch Neurol 2009, 66:226-33. CrossRef
21. Stankovich J, Butzkueven H, Marriott M, Chapman C, Tubridy N, Tait BD, / et al.: HLA-DRB1 associations with disease susceptibility and clinical course in Australians with multiple sclerosis. / Tissue Antigens 2009, 74:17-1. CrossRef
22. Ku?inskas V: Genetic diversity of population. / Genetics 2001, 6:160-71.
23. Wu J-S, Qiu W, Castley A, James I, Mastaglia FL, Christiansen FT, / et al.: Modifying effects of HLA-DRB1 allele interactions on age at onset of multiple sclerosis in Western Australia. / Mult Scler 2010, 16:15-0. CrossRef
24. Barcellos LF, Sawcer S, Ramsay PP, Baranzini SE, Thompson G, Briggs F, / et al.: Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. / Hum Mol Genet 2006, 18:2813-824. CrossRef
25. Matsuoka T, Matsushita T, Oseogawa M, Kawano Y, Minohara M, Mihara F, / et al.: Association of HLA DRB1 alleles with characteristic MRI features of Asian multiple sclerosis. / Mult Scler 2008, 14:1181-190. CrossRef
26. Wu J-S, Qiu W, Castley A, James I, Joseph J, Christiansen FT, / et al.: Clinical profile and HLA-DRB1 genotype of late onset multiple sclerosis in Western Australia. / J of Clinical Neuroscience 2010, 17:1009-013. CrossRef
27. Idiman E, Ozakbas S, Dogan Y, Kosehasanogullari G: The significance of oligoclonical bands in multiple sclerosis: relevance of demographic and clinical features, and immunogenetic backgrounds. / J Neuroimmunol 2009, 212:121-24. CrossRef
28. Romero-Pinel L, Yelamos-Martinez S, Bau L, Matas E, Guberias L, Maria Pujai J, / et al.: Association of HLA DRB1*15 allele and CSF oligoclonal bands in a Spanish multiple sclerosis cohort. / Eur J Neurol 2011, 10:1258-262. CrossRef
29. Wu J-S, Qui W, Castley A, James I, Joseph J, Christiansen FT, / et al.: Presence of CSF oligoclonal bands is associated with the HLA-DRB1 genotype in a West Australian multiple sclerosis cohort. / J Neuroimmunol 2010, 288:63-7.
30. Obermeier B, Mentele R, Malotka J, Kellermann J, Kumpfel T, Wekerle H, / et al.: Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. / Nat Med 2008, 14:688-93. CrossRef
31. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2377/13/77/prepub - 作者单位：Renata Balnyte (1)
Daiva Rastenyte (1)
Antanas Vaitkus (1)
Dalia Mickeviciene (1)
Erika Skrodeniene (2)
Astra Vitkauskiene (2)
Ingrida Uloziene (3)
1. Department of Neurology, Academy of Medicine, Lithuanian University of Health Sciences, A. Mickeviciaus street 9, Kaunas, LT, 44307, Lithuania
2. Department of Laboratory Medicine, Academy of Medicine, Lithuanian University of Health Sciences, A. Mickeviciaus street 9, Kaunas, LT, 44307, Lithuania
3. Department of Otorinolaryngology, Academy of Medicine, Lithuanian University of Health Sciences, A. Mickeviciaus street 9, Kaunas, LT, 44307, Lithuania
文摘
Background The association of HLA DRB1 alleles with susceptibility to multiple sclerosis (MS) has been consistently reported although its effect on the clinical features and disability is still unclear probably due to diversity in ethnicity and geographic location of the studied populations. The aim of the present study was to investigate the influence of HLA DRB1 alleles on the clinical features and disability of the patients with MS in Lithuania. Methods This was a prospective study of 120 patients with MS. HLA DRB1 alleles were genotyped using the polymerase chain reaction. Results The first symptoms of MS in patients with HLA DRB1*15 allele manifested at younger age than in those without this allele (28.32 +/?5.49 yrs vs. 30.94 +/?8.43 yrs, respectively, p--.043). HLA DRB1*08 allele was more prevalent among relapsing-remitting (RR) MS patients than among patients with progressive course of MS (25.0% vs. 8.3%, respectively, chi^2--.000, p--.05). MS patients with this allele had lower relapse rate than those without this allele (1.00 +/?0.97 and 1.44 +/?0.85, respectively, p--.043). Degree of disability during the last visit was lower among the patients with HLA DRB1*08 allele (EDSS score 3.15 +/?1.95 vs. 4.49 +/?1.96, p--.006), and higher among those with HLA DRB1*15 allele (EDSS score 4.60 +/?2.10 vs.4.05 +/?1.94, p--.047) compared to patients without these alleles but there were no significant associations between these alleles and the duration of the disease to disability. HLA DRB1*08 allele (OR--.18, 95% CI 0,039-0,8, p--.029) was demonstradet to be independent factor to take a longer time to reach an EDSS of 6, while HLA DRB1*01 allele (OR--.92, 95% CI 1,30-26,8, p--.021) was related in a shorter time to reach and EDSS of 6. Patients with HLA DRB1*08 allele had lower IgG index compared to patients without this allele (0.58 +/?0.17 and 0.73 +/?0.31, respectively, p--.04), and HLA DRB1*15 allele was more often found among MS patients with oligoclonal bands (OCBs) in cerebrospinal fluid than among those without OCBs (OR 2.3, CI 95% 1.017-5.301; p--.043). Conclusions HLA DRB1*15 allele was related with an earlier manifestation of the first MS symptoms, progressive course of the disease and higher degree of disability. HLA DRB1*08 allele was more prevalent among the RR MS patients and was associated with the lower rate of relapse, degree of disability and IgG index.